First-in-human Evaluation of [18F]CETO

NCT05361083 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Primary Aldosteronism Due to Aldosterone Producing Adenoma
Primary Aldosteronism Due to Nodular Hyperplasia
Adrenal Cushing Syndrome
Non-Secretory Adrenal Adenoma
Adrenocortical Carcinoma

Interventions

DRUG: F18CETO

Sponsor

Uppsala University

Collaborators

[object Object]
[object Object]